share_log

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

福泰制药 | 144:拟议出售证券
美股SEC公告 ·  08/08 11:49

Moomoo AI 已提取核心信息

Vertex Pharmaceuticals Inc. Director Sangeeta N. Bhatia is set to sell 1,292 shares of common stock on 08/08/2024, according to a recent filing. The shares, valued at an aggregate market price of $602,446.68, were originally acquired on the same date through options granted on 06/01/2018. The transaction will be conducted with cash as the nature of payment. No other sales of securities have been reported by Bhatia in the past three months.
Vertex Pharmaceuticals Inc. Director Sangeeta N. Bhatia is set to sell 1,292 shares of common stock on 08/08/2024, according to a recent filing. The shares, valued at an aggregate market price of $602,446.68, were originally acquired on the same date through options granted on 06/01/2018. The transaction will be conducted with cash as the nature of payment. No other sales of securities have been reported by Bhatia in the past three months.
Vertex Pharmaceuticals Inc.董事Sangeeta N. Bhatia将于2024年08月08日卖出1,292股普通股,根据最近的文件显示。这些股票的市场总价值为$602,446.68,最初是在2018年06月01日授予期权时获得的。交易将采用现金支付方式进行。 Bhatia在过去三个月中未报告出售其他证券。
Vertex Pharmaceuticals Inc.董事Sangeeta N. Bhatia将于2024年08月08日卖出1,292股普通股,根据最近的文件显示。这些股票的市场总价值为$602,446.68,最初是在2018年06月01日授予期权时获得的。交易将采用现金支付方式进行。 Bhatia在过去三个月中未报告出售其他证券。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息